Randomized phase three trial on patients with epidermal growth factor (EGFR) mutation stage II-IIIA non-small cell lung cancer (NSCLC) gave adjuvant Gefitinib (G) treatment versus vinorelbine plus cisplatin (VP) to assess overall survival (OS). The gene discussed is EGF; the disease is non-small cell lung carcinoma.